Literature DB >> 10625719

Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.

D Z Wang1, J A Rose, D S Honings, D J Garwacki, J C Milbrandt.   

Abstract

BACKGROUND AND
PURPOSE: Since the FDA approved tissue plasminogen activator (tPA) in 1996 for acute ischemic stroke, few data have been obtained during the postmarketing phase, and applicability in rural hospitals does not exist. We attempt to examine the safety and outcome of intravenous tPA for acute ischemic stroke in the OSF Stroke Network.
METHODS: Fifty-seven consecutive patients treated with tPA were examined from June 1996 through December 1998. Admission and discharge National Institute of Health Stroke Scales (NIHSS), modified Rankin Scales (MRS), and discharge disposition, as well as intracerebral hemorrhage and mortality rates, were compared.
RESULTS: Of 20 network hospitals, 12 had the experience of administering tPA. No statistically significant differences in the variables recorded were observed for patients treated at the community hospitals versus those who received tPA at the tertiary medical center. In 35% of patients, tPA was initiated by an emergency room or primary care physician in consultation with an OSF neurologist. At discharge, 47% of the patients had minimal or no disability (MRS, 0 to 1), 44% had an NIHSS score of 0 or 1, 54% went home, 25% were transferred to in-patient rehabilitation, 12% went to a nursing or skilled-care facility, and 9% died. Intracerebral hemorrhage rate was 9%; 5% were symptomatic.
CONCLUSIONS: tPA can be administered safely with good outcome at community and rural hospitals. The OSF Stroke Network can serve as a model to assist small community hospitals to set up stroke programs and deliver up-to-date, acute stroke therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625719     DOI: 10.1161/01.str.31.1.77

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  34 in total

Review 1.  Optimal timing of thrombolytic therapy in acute ischaemic stroke.

Authors:  Ken Madden
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2009-05

3.  Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Authors:  Phillip A Scott; Shirley M Frederiksen; John D Kalbfleisch; Zhenzhen Xu; William J Meurer; Angela F Caveney; Annette Sandretto; Ann B Holden; Mary N Haan; Ellen G Hoeffner; Sameer A Ansari; David P Lambert; Michael Jaggi; William G Barsan; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

Review 4.  Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice.

Authors:  Dawn M Bravata
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  From the inside looking out: a view from the fishbowl.

Authors:  J Stephen Huff; Jonathan A Edlow; Scott Silvers
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

6.  Reasons to withhold intra-arterial thrombolysis in clinical practice.

Authors:  J Isenegger; K Nedeltchev; M Arnold; U Fischer; G Schroth; L Remonda; H P Mattle
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 7.  Organization of regional and local stroke resources: methods to expedite acute management of stroke.

Authors:  James Kennedy; Christina Ma; Alastair M Buchan
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

8.  Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset.

Authors:  Moon-Ku Han; Sung Hyun Kim; Sang-Bae Ko; Nam-Jong Paik; O-Ki Kwon; Yong-Seok Lee; Chang-Wan Oh; Jae Hyoung Kim; Seong-Ho Park; Hee-Joon Bae
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 9.  Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation.

Authors:  Phillip A Scott
Journal:  Emerg Med Clin North Am       Date:  2009-02       Impact factor: 2.264

10.  Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.